TR201808823T4 - Rekombinant vwf nin uygulanması vasıtasıyla koagülasyon hastalığının tedavisi. - Google Patents

Rekombinant vwf nin uygulanması vasıtasıyla koagülasyon hastalığının tedavisi. Download PDF

Info

Publication number
TR201808823T4
TR201808823T4 TR2018/08823T TR201808823T TR201808823T4 TR 201808823 T4 TR201808823 T4 TR 201808823T4 TR 2018/08823 T TR2018/08823 T TR 2018/08823T TR 201808823 T TR201808823 T TR 201808823T TR 201808823 T4 TR201808823 T4 TR 201808823T4
Authority
TR
Turkey
Prior art keywords
rvwf
fviii
compound
rfviii
stability
Prior art date
Application number
TR2018/08823T
Other languages
English (en)
Turkish (tr)
Inventor
Scheiflinger Friedrich
Turecek Peter
Ewenstein Bruce
Yen Wong Wing
M Suiter Tobias
Original Assignee
Baxalta GmbH
Baxalta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxalta GmbH, Baxalta Inc filed Critical Baxalta GmbH
Publication of TR201808823T4 publication Critical patent/TR201808823T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
TR2018/08823T 2011-06-10 2012-06-11 Rekombinant vwf nin uygulanması vasıtasıyla koagülasyon hastalığının tedavisi. TR201808823T4 (tr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161495884P 2011-06-10 2011-06-10
US201161511901P 2011-07-26 2011-07-26
US201161523790P 2011-08-15 2011-08-15

Publications (1)

Publication Number Publication Date
TR201808823T4 true TR201808823T4 (tr) 2018-07-23

Family

ID=46321496

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2018/08823T TR201808823T4 (tr) 2011-06-10 2012-06-11 Rekombinant vwf nin uygulanması vasıtasıyla koagülasyon hastalığının tedavisi.

Country Status (24)

Country Link
US (3) US9272021B2 (enExample)
EP (3) EP3412305B1 (enExample)
JP (3) JP6347468B2 (enExample)
KR (3) KR20190041032A (enExample)
CN (3) CN103732244A (enExample)
AR (1) AR086904A1 (enExample)
AU (5) AU2012267458A1 (enExample)
BR (1) BR112013031795A2 (enExample)
CA (1) CA2838845C (enExample)
DK (3) DK3858375T3 (enExample)
ES (3) ES2860450T3 (enExample)
FI (1) FI3858375T3 (enExample)
HK (1) HK1257436A1 (enExample)
HR (1) HRP20180962T1 (enExample)
HU (1) HUE039317T2 (enExample)
LT (1) LT2717905T (enExample)
MX (2) MX350582B (enExample)
PL (3) PL2717905T3 (enExample)
PT (3) PT3412305T (enExample)
RU (2) RU2628537C2 (enExample)
SG (2) SG10201604684WA (enExample)
SI (1) SI2717905T1 (enExample)
TR (1) TR201808823T4 (enExample)
WO (1) WO2012171031A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190041032A (ko) * 2011-06-10 2019-04-19 박스알타 인코퍼레이티드 재조합 vwf의 투여에 의한 응고 질환의 치료
CN102776260B (zh) * 2012-07-26 2015-04-29 上海泰龙生物医药科技有限公司 一种高效表达重组人凝血八因子的方法
DK2796145T3 (da) 2013-04-22 2018-01-29 Csl Ltd Et kovalent kompleks af von Willebrand-faktor og faktor VIII linket af en disulfidbro
NL2013007B1 (en) 2014-06-16 2016-07-05 Ablynx Nv Methods of treating TTP with immunoglobulin single variable domains and uses thereof.
FR3034669B1 (fr) * 2015-04-07 2020-02-14 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Nouvelle utilisation du facteur von willebrand
EP4343774A3 (en) 2016-04-15 2024-06-05 Takeda Pharmaceutical Company Limited Method and apparatus for providing a pharmacokinetic drug dosing regiment
US10896749B2 (en) 2017-01-27 2021-01-19 Shire Human Genetic Therapies, Inc. Drug monitoring tool
RU2766118C2 (ru) * 2017-07-07 2022-02-08 Такеда Фармасьютикал Компани Лимитед Лечение пациентов с тяжелой формой болезни фон виллебранда, подвергающихся плановому хирургическому вмешательству, путем введения рекомбинантного ффв
EP4424366A3 (en) * 2017-07-07 2024-12-04 Takeda Pharmaceutical Company Limited Treatment of gastrointestinal bleeding in patients with severe von willebrand disease by administration of recombinant vwf
SG11202006902QA (en) 2018-02-06 2020-08-28 Ablynx Nv Methods of treating initial episode of ttp with immunoglobulin single variable domains
EP3768697A1 (en) * 2018-03-21 2021-01-27 Baxalta Incorporated Separation of vwf and vwf propeptide by chromatographic methods
MX2021009114A (es) * 2019-02-01 2021-10-13 Takeda Pharmaceuticals Co Métodos de tratamiento profiláctico que usan factor de von willebrand recombinante (rvwf).
JP2022547556A (ja) * 2019-09-11 2022-11-14 武田薬品工業株式会社 フォン・ヴィレブランド因子と補体ｃ１ｑの複合体に関連する治療法
CN115335074A (zh) 2020-02-04 2022-11-11 武田药品工业株式会社 通过施用重组vwf来治疗患有重度冯维勒布兰德病的患者的月经过多
TW202237149A (zh) * 2020-11-24 2022-10-01 美商邦德治療公司 用於治療出血性障礙之組成物及方法
WO2024124136A1 (en) * 2022-12-09 2024-06-13 Vega Therapeutics, Inc. Von willebrand disease animal models

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4638028A (en) 1985-04-08 1987-01-20 Goodyear Tire & Rubber Company Rubber polymerases and methods for their production and use
EP0218692A4 (en) 1985-04-11 1988-03-22 Childrens Medical Center VON WILLEBRAND FACTOR.
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
SE504074C2 (sv) * 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
DE4435485C1 (de) * 1994-10-04 1996-03-21 Immuno Ag Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor
AT403764B (de) * 1996-03-15 1998-05-25 Immuno Ag Stabiler faktor viii/vwf-komplex
AT405403B (de) * 1997-02-27 1999-08-25 Immuno Ag Reinigung von von willebrand-faktor durch kationenaustauscherchromatographie
AT406373B (de) * 1997-02-27 2000-04-25 Immuno Ag Verfahren zur reinigung von faktor viii/vwf-komplex mittels kationenaustauscherchromatographie
US6531577B1 (en) 1997-12-15 2003-03-11 Hemasure Denmark A/S von Willebrand factor (vWF)-containing preparation, process for preparing vWF-containing preparations, and use of such preparations
US6864403B1 (en) 1998-10-15 2005-03-08 E. I. Du Pont De Nemours And Company Plant protein disulfide isomerases
US20040014657A1 (en) * 2001-11-05 2004-01-22 Jan Ohrstrom Use of blood coagulation factor XIII for treating haemophilia A
WO2005012354A1 (en) * 2003-07-31 2005-02-10 Zlb Behring Gmbh Method for extending the half-life of fviii
EP1593388A1 (en) 2004-05-05 2005-11-09 ZLB Behring GmbH Therapeutic plasma protein-concentrates containing von willebrand factor as high molecular weight multimers
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
AU2005322067B8 (en) * 2004-12-27 2012-07-26 Takeda Pharmaceutical Company Limited Polymer-von Willebrand factor-conjugates
DK1974014T3 (en) 2006-01-04 2017-06-19 Baxalta Inc OLIGOPEPTID-FREE CELL CULTURE MEDIA
ES2392569T3 (es) * 2007-06-13 2012-12-11 Csl Behring Gmbh Uso de preparaciones FVIII estabilizadas VWF para administración extravascular en la terapia y el tratamiento profiláctico de trastornos de hemorragias
EP2222329A1 (en) 2007-11-09 2010-09-01 Baxter International Inc. Modified recombinant factor viii and von willebrand factor and methods of use
JP2009127455A (ja) 2007-11-20 2009-06-11 Bando Kiko Co Ltd 往復動エンジン
MX2010007150A (es) * 2007-12-28 2010-09-03 Baxter Int Formulaciones del factor de von-willebrand recombinante.
ES2298096B1 (es) * 2008-01-08 2009-01-01 Grifols, S.A. Procedimiento para la obtencion de un concentrado de factor von willebrand o del complejo de factor viii/factor von willebrand y utilizacionde los mismos.
ES2531464T3 (es) * 2008-06-24 2015-03-16 Csl Behring Gmbh Factor VIII, factor de von Willebrand o sus complejos con semivida in vivo prolongada
KR101772674B1 (ko) 2008-10-21 2017-09-01 박스알타 인코퍼레이티드 동결건조된 재조합 ｖｗｆ 제제
WO2011017414A2 (en) * 2009-08-04 2011-02-10 Baxter International Inc. Transgenic mouse lacking endogenous fviii and vwf - a model of hemophilia a
HRP20180136T1 (hr) 2010-07-08 2018-04-06 Baxalta GmbH POSTUPAK PROIZVODNJE REKOMBINANTNOG VISOKOMOLEKULSKOG vWF U KULTURI STANICA
US20120006800A1 (en) 2010-07-09 2012-01-12 Illinois Tool Works Inc. Weld bead feature communication systems and devices
KR20190041032A (ko) * 2011-06-10 2019-04-19 박스알타 인코퍼레이티드 재조합 vwf의 투여에 의한 응고 질환의 치료

Also Published As

Publication number Publication date
DK2717905T3 (en) 2018-07-02
AU2020200026A1 (en) 2020-01-30
EP3858375A1 (en) 2021-08-04
CA2838845C (en) 2019-08-06
US20120316116A1 (en) 2012-12-13
AU2016202299B2 (en) 2017-07-20
MX2013014543A (es) 2014-06-11
LT2717905T (lt) 2018-10-10
SI2717905T1 (sl) 2018-09-28
BR112013031795A2 (pt) 2016-12-20
DK3858375T3 (da) 2024-04-15
KR20200091476A (ko) 2020-07-30
EP3858375B1 (en) 2024-03-20
US9272021B2 (en) 2016-03-01
JP6347468B2 (ja) 2018-06-27
JP6527114B2 (ja) 2019-06-05
AU2012267458A1 (en) 2014-01-09
CN103732244A (zh) 2014-04-16
CA2838845A1 (en) 2012-12-13
JP2019048892A (ja) 2019-03-28
RU2019103386A3 (enExample) 2022-01-24
JP2014516088A (ja) 2014-07-07
CN108210889A (zh) 2018-06-29
ES2860450T3 (es) 2021-10-05
NZ618790A (en) 2015-07-31
KR102319868B1 (ko) 2021-11-01
KR20190041032A (ko) 2019-04-19
RU2680402C2 (ru) 2019-02-21
ES2682249T3 (es) 2018-09-19
PL3412305T3 (pl) 2021-05-31
HRP20180962T1 (hr) 2018-10-19
EP3412305B1 (en) 2021-01-06
HK1257436A1 (zh) 2019-10-18
MX2020000083A (es) 2020-08-06
ES2976169T3 (es) 2024-07-24
EP3412305A1 (en) 2018-12-12
RU2014100107A (ru) 2015-07-20
US20250387455A1 (en) 2025-12-25
AU2016202299A1 (en) 2016-05-05
AU2022201518B2 (en) 2025-07-03
EP2717905A1 (en) 2014-04-16
AR086904A1 (es) 2014-01-29
KR101969515B1 (ko) 2019-04-16
PL3858375T3 (pl) 2024-05-20
FI3858375T3 (fi) 2024-04-17
AU2022201518A1 (en) 2022-03-24
PT2717905T (pt) 2018-07-02
DK3412305T3 (da) 2021-03-01
HUE039317T2 (hu) 2018-12-28
JP2017019788A (ja) 2017-01-26
PL2717905T3 (pl) 2018-10-31
WO2012171031A1 (en) 2012-12-13
MX350582B (es) 2017-09-11
EP2717905B1 (en) 2018-05-23
PT3858375T (pt) 2024-04-18
RU2019103386A (ru) 2020-08-07
RU2628537C2 (ru) 2017-08-18
CN107412743A (zh) 2017-12-01
SG10202002591QA (en) 2020-05-28
RU2017102679A3 (enExample) 2018-12-19
AU2017206235A1 (en) 2017-08-03
US20160184403A1 (en) 2016-06-30
CN107412743B (zh) 2021-07-02
SG10201604684WA (en) 2016-07-28
RU2017102679A (ru) 2018-12-19
KR20140039285A (ko) 2014-04-01
AU2017206235B2 (en) 2019-10-17
PT3412305T (pt) 2021-01-29

Similar Documents

Publication Publication Date Title
TR201808823T4 (tr) Rekombinant vwf nin uygulanması vasıtasıyla koagülasyon hastalığının tedavisi.
ES2875772T3 (es) Método de producción de ADAMTS13 recombinante en cultivo celular
ES2733220T3 (es) Proteína de fusión de hGH-XTEN y su uso en el tratamiento de la deficiencia de la hormona del crecimiento
JP2015527350A (ja) 第ｖｉｉｉ因子の液体製剤
KR20110071012A (ko) 낮은 수준의 수용성 중합체를 포함하는 개질된 혈액 인자
JP7641327B2 (ja) 組換えｖｗｆの投与による重度のフォンヴィレブランド病を患う患者における消化管出血の治療
JP2014532076A (ja) 第ｖｉｉｉ因子のバイオアベイラビリティを改善するための、硫酸化グリコサミノグリカン及びヒアルロニダーゼの組み合わせ使用
ES2751361T3 (es) Factor VIII de la coagulación con inmunogenicidad reducida
JP7326246B2 (ja) 待機手術を受ける、重度のフォンヴィレブランド病を患う患者の、組換えｖｗｆの投与による治療法
US20260014236A1 (en) Activators of coagulation factor x and formulations thereof for treating bleeding disorders
WO2023246680A1 (en) Activators of coagulation factor x and formulations thereof for treating bleeding disorders
AU2018294517B2 (en) 21-day dosing regimen for fusion proteins comprising factor IX and human albumin for prophylactic treatment of hemophilia and methods thereof
HK40056758A (en) Treatment of coagulation disease by administration of recombinant vwf
JP2023514541A (ja) 組換えｖｗｆの投与による重症のフォンヴィレブランド病患者における過多月経の治療
HK40056758B (en) Treatment of coagulation disease by administration of recombinant vwf
HK40001633B (en) Treatment of coagulation disease by administration of recombinant vwf
HK1196768B (en) Treatment of coagulation disease by administration of recombinant vwf
HK1196768A (en) Treatment of coagulation disease by administration of recombinant vwf
BR112015031194B1 (pt) Molécula quimérica, composição farmacêutica, e uso dos anteriores